Mária Zeliesková, Miloš Jeseňák, Peter Bánovčin
Omalizumab is a humanized monoclonal anti-IgE antibody whose introduction into clinical practice has been a substantial
milestone in the management of severe asthma. Officially approved indications for treatment with omalizumab
currently include also severe and refractory forms of chronic spontaneous urticaria (CSU) in adults and children over
12 years of age. Our work presents the case of patient with the diagnosis of severe CSU, undergoing 6-months long
omalizumab cycle treatment at the age of 8. Administration of this biological medication has led to remission of the
disease, while no adverse effects have been observed. In our case report we would like to point out the significant status
of omalizumab in the CSU management in pediatric patients that could be included in standard therapeutic procedures
for children younger than 12 years of age after efficacy and safety confirmation.